KIT and gastrointestinal stromal tumor: At most GIST centers, patients with KIT-mutant GIST are treated sequentially with imatinib, sunitinib, regorafenib and ripretinib, as first- to fourth-line therapies, based on progression or intolerance during the previous line of the therapy21.